Why European Experts Cautiously Recommend Pembrolizumab to Treat High-Risk Kidney Cancer Following Surgery

Video
Conference|Society of Urologic Oncology Annual Meeting (SUO)

Despite the observed disease-free survival benefit associated with pembrolizumab in high-risk kidney cancer after surgery, the European Association of Urology guidelines maintain a weak recommendation for its use.

Although pembrolizumab (Keytruda) yielded a statistically significant benefit in terms of disease-free survival (DFS) in patients with high-risk renal cell carcinoma after surgery, a panel of experts cautiously recommend its use as an adjuvant therapy.

Axel Bex, MD, PhD, a urologic surgeon at the Specialist Centre For Kidney Cancer, Royal Free London NHS Foundation Trust, and a professor at University College London, Division of Surgery and Interventional Science, spoke with CancerNetwork® during the 2022 Society for Urologic Oncology (SUO) Annual Meeting about the updated efficacy findings from the KEYNOTE-564 trial and why the European Association of Urology (EAU) gave pembrolizumab a weak recommendation.1

In the KEYNOTE-564 trial, the DFS benefit of pembrolizumab was indicated with a hazard ratio of 0.63 (95% CI, 0.50-0.80; P < .0001).

However, given the negative findings of other kidney cancer trials investigating immune checkpoint inhibitors, the EAU updated guidelines in October 2022 reaffirming a weak recommendation for offering adjuvant pembrolizumab to patients with clear cell renal cell carcinoma.2 Additionally, authors of the guidelines, including Bex, recommended robust discussion with patients about results from other clinical trials and the potential for overtreatment when offering pembrolizumab as therapy to patients.

Transcript:

We had 1 positive trial, which was KEYNOTE-564, which was investigating pembrolizumab. We had a recent update in which the hazard ratio was 0.63, which is statistically significant for disease-free survival, which also means it's a reduction of 37% in the risk of progressing and recurring or dying from a disease, which is very a positive result. The reason why we decided to take this weak recommendation [from the EAU panel] is because there's an early overall survival signal, which is not yet statistically significant but may turn out to be statistically significant.

References

  1. Choueiri TK, Tomczak P, Park SH, et al. Pembrolizumab as post nephrectomy adjuvant therapy for patients with renal cell carcinoma: Results from 30-month follow-up of KEYNOTE-564. J Clin Oncol. Published online February 16, 2022. doi:10.1200/JCO.2022.40.6
  2. Bedke J, Albiges L, Capitanio U, et al. The 2022 Updated European Association of Urology Guidelines on the use of adjuvant immune checkpoint inhibitor therapy for renal cell carcinoma. European Urology. 2022;83(1):10-14. doi:10.1016/j.eururo.2022.10.010
Recent Videos
Patients with mediastinal lymph node involved-lung cancer may benefit from chemoimmunotherapy in the neoadjuvant setting.
Stressing the importance of prompt AE disclosure before they become severe can ensure that a patient can still undergo resection with curative intent.
Thomas Marron, MD, PhD, presented a session on clinical data that established standards of care for stage II and III lung cancer treatment at CFS 2025.
Sonia Jain, PhD, stated that depatuxizumab mafodotin, ABBV-221, and ABBV-321 were 3 of the most prominent ADCs in EGFR-amplified glioblastoma.
Skin toxicities are common with targeted therapies for GI malignancies but can be remedied by preventative measures and a collaboration with dermatology.
Computational models help researchers anticipate how ADCs may behave in later lines of development, while they are still in the early stages.
ADC payloads with high levels of potency can sometimes lead to higher levels of toxicity, which can eliminate the therapeutic window for patients with cancer.
According to Greg Thurber, PhD, target-mediated uptake is the biggest driver of efficacy for antibody-drug conjugates as a cancer treatment.
Antibody-drug conjugates are effective, but strategies such as better understanding the mechanisms of action may lead to enhanced care for patients with cancer. Antibody-drug conjugates are effective, but strategies such as better understanding the mechanisms of action may lead to enhanced care for patients with cancer.
Related Content
A first-in-human phase 1/2 trial is evaluating the theranostic pair of ITM-91 and ITM-94 in patients with solid tumors.

FDA Grants Fast Track Designation to Novel Imaging Agent in Clear Cell RCC

Tim Cortese
November 17th 2025
Article

A first-in-human phase 1/2 trial is evaluating the theranostic pair of ITM-91 and ITM-94 in patients with solid tumors.

Experts highlight the top 5 presentations from ESMO 2025 that may have long-term clinical implications for genitourinary cancer management.

What Were The Most Impactful GU Oncology Data From ESMO 2025?

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
November 6th 2025
Podcast

Experts highlight the top 5 presentations from ESMO 2025 that may have long-term clinical implications for genitourinary cancer management.

There is a lot of excitement among experts in the field of antibody-drug conjugates as new developments continue to come out in various disease states.

The Latest and Hottest Topics in ADCs: A Discussion With a Chemical Engineer

Tim Cortese
November 15th 2025
Article

There is a lot of excitement among experts in the field of antibody-drug conjugates as new developments continue to come out in various disease states.

Presenting investigators at ESMO Congress 2025 highlight findings from clinical trials assessing novel therapeutics across different disease types.

What Were the Key Presentations at ESMO 2025? Oncology Experts Discuss

Sara A. Hurvitz, MD;Xiuning Le, MD, PhD;Erica L. Mayer, MD, MPH
October 27th 2025
Podcast

Presenting investigators at ESMO Congress 2025 highlight findings from clinical trials assessing novel therapeutics across different disease types.

Although the study was underpowered due to a small sample size, non-significant improvements in functional and social well-being occurred with MOST-S26.

Nurse-Led Telehealth Displays Feasibility in Ovarian Cancer Follow-Up

Roman Fabbricatore
November 14th 2025
Article

Although the study was underpowered due to a small sample size, nonsignificant improvements in functional and social well-being occurred with MOST-S26.

At 1 and 2 years, the progression-free survival rates were higher with nivolumab plus ipilimumab vs pembrolizumab in patients with cutaneous melanoma.

Nivolumab/Ipilimumab Improves Real-World Melanoma Outcomes Vs Pembrolizumab

Russ Conroy
November 12th 2025
Article

At 1 and 2 years, the progression-free survival rates were higher with nivolumab plus ipilimumab vs pembrolizumab in patients with cutaneous melanoma.